Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

Ítems similars

• Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
  per: Paz-Ares, Luis, et al.
  Publicat: (2014)
• ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer
  per: Moecks, Joachim, et al.
  Publicat: (2015)
• Reply to Watkins and Rukazenkov (J Cell Mol Med 2010), re-Letter of Response to manuscript entitled ‘Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis’ (Paz-Ares et al., J Cell Mol Med. 2010; 14(1–2): 51–69)
  per: Paz-Ares, Luis, et al.
  Publicat: (2011)
• Co-mutations in EGFR driven non-small cell lung cancer
  per: Rosell, Rafael, et al.
  Publicat: (2019)
• Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
  per: Karachaliou, Niki, et al.
  Publicat: (2014)